Organogenesis
ORGO

Organogenesis (ORGO) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Truist SecuritiesMaintainedHold$2.00 from $3.00Aug 7, 2026
Truist SecuritiesInitiated CoverageHold$3.00May 28, 2026
BTIGMaintainedBuy$8.00Mar 26, 2026
BTIGMaintainedBuy$8.00 from $9.00Feb 27, 2026
BTIGMaintainedBuy$9.00Dec 26, 2025
BTIGMaintainedBuy$9.00Dec 15, 2025
BTIGMaintainedBuy$9.00 from $7.00Nov 20, 2025
BTIGMaintainedBuy$7.00Sep 26, 2025
Cantor FitzgeraldMaintainedOverweight$9.00 from $7.00Aug 8, 2025
Cantor FitzgeraldMaintainedOverweight$7.00Jul 15, 2025
Morgan StanleyMaintainedEqual-Weight$6.00 from $4.00Mar 5, 2025
Cantor FitzgeraldMaintainedOverweight$5.00Mar 1, 2024
Cantor FitzgeraldInitiated CoverageOverweight$5.00Feb 7, 2024
BTIGMaintainedBuy$6.00 from $4.00Dec 27, 2023
Morgan StanleyMaintainedEqual-Weight$3.50 from $3.00Nov 14, 2023
Morgan StanleyMaintainedEqual-Weight$3.00 from $5.00Aug 11, 2023
BTIGMaintainedBuy$4.00 from $10.00Aug 10, 2023
BTIGUpgradedNeutral → Buy$10.00May 24, 2023

Frequently asked questions

  • What is the latest analyst rating on ORGO?

    On Aug 7, 2026, Truist Securities maintained Organogenesis at Hold with a price target of $2.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.